Work

Chemistry, manufacturing and controls strategies for using novel excipients in lipid nanoparticles

Year: 2025

Type: review

Source: Nature Nanotechnology

DOI: 10.1038/s41565-024-01833-9

Authors: Matthew O’Brien Laramy, David A. Foley, Roger H. Pak, Jacob A. Lewis, Eric McKinney, Patricia M. Egan, Ravikiran Yerabolu, Eric Dane, Olivier Dirat, Lindsey Saunders Gorka, Joseph R. Martinelli, Ehab M. Moussa, Julie Barthuet

Institutions: Genentech, Merck & Co., Inc., Rahway, NJ, USA (United States), Pfizer (United States), Amgen (United States), Alnylam Pharmaceuticals (United States), AstraZeneca (United States), Pfizer (United Kingdom), Eli Lilly (United States), AbbVie (United States), Sanofi (France)

Language: English

Topic: RNA Interference and Gene Delivery

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4406472327

FWCI: 4.57

Cites: 68

Cited by: 52

Related to: 10